Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder

Next Previous
X
Search
Trial Profile

An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications REM-sleep-behavior-disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sio Gene Therapies [CEASED]

    • Most Recent Events

    • 10 Dec 2018 According to an Axovant media release, based on the data of the pilot study (RVT102-2002) , which did not meet the primary endpoint, the company has discontinued the clinical development of the Nelotanserin for the treatment of REM sleep behavior disorder (RBD) in patients with Lewy body dementia (LBD).
    • 10 Dec 2018 Status changed from active, no longer recruiting to discontinued, according to an Axovant media release.
    • 22 Oct 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top